Lupin's Solosec Shows 92-95% Cure Rate in Phase 3 Trichomoniasis Trial, Expanding Treatment Options for Common STI
核心洞察
Lupin's Phase 3 trial demonstrated that single-dose Solosec (secnidazole) achieved a 92-95% microbiological cure rate in female patients with trichomoniasis (搜索) versus 1.5-1.7% with placebo.
The company plans to submit a supplemental New Drug Application to the FDA later this year to expand Solosec's indication beyond bacterial vaginosis (搜索) to include trichomoniasis (搜索) treatment.
Trichomoniasis (搜索) affects an estimated 3-5 million people in the U.S. and is the most common non-viral, curable sexually transmitted infection, with African American women facing nearly ten times higher risk.
Lupin Pharmaceuticals has announced positive results from its pivotal Phase 3 clinical trial evaluating single-dose Solosec (secnidazole) 2g oral granules for treating trichomoniasis (搜索) in female patients. The trial demonstrated a clinically and statistically significant response rate, with 92-95% of patients achieving microbiological cure compared to just 1.5-1.7% in the placebo group (p<0.001).
The results were presented at the 2020 Infectious Diseases Society for Obstetrics & Gynecology (IDSOG) Virtual Annual Meeting and represent a potential expansion of Solosec's therapeutic applications beyond its current FDA-approved indication for bacterial vaginosis (搜索).
Trial Results and Clinical Significance
The Phase 3 multicenter, randomized, delayed treatment, placebo-controlled, double-blind study enrolled 147 adult female patients diagnosed with trichomoniasis (搜索) confirmed by positive culture for T. vaginalis. The trial met its primary endpoint of microbiological cure at the test-of-cure visit on study Day 6-12.
In the modified Intent-To-Treat population, 92.2% of patients in the Solosec group (59/64) achieved the primary endpoint versus 1.5% (1/67) in the placebo group. The Per-Protocol population showed even higher efficacy, with a cure rate of 94.9% (56/59) for Solosec versus 1.7% (1/60) for placebo.
"The efficacy results of the Phase 3 study are quite encouraging and could support the utility of Solosec in clinical practice as a treatment option for trichomoniasis (搜索) once the new indication is approved," said Christina Muzny, M.D., MSPH, University of Alabama at Birmingham, who presented the abstract at IDSOG.
Safety Profile and Tolerability
Solosec was generally well-tolerated in the trial, with the most commonly reported adverse events being vulvovaginal candidiasis (搜索) (2.7%) and nausea (2.7%). No serious adverse events were observed during the study period.
Addressing an Unmet Medical Need
Trichomoniasis (搜索) represents a significant public health challenge as the most common non-viral sexually transmitted infection in the United States. The infection affects an estimated 3-5 million people, with African American women facing nearly ten times higher risk compared to non-Hispanic white women. The condition is four-to-five times more prevalent in women than men.
"Trichomoniasis (搜索) increases risk of HIV infection (搜索), disproportionately affects African American women and can lead to adverse health outcomes," noted Dr. Muzny. "It is critical to screen women at high risk and treat with therapy that is convenient to use, to help improve patient compliance."
The infection is associated with a two- to three-fold increased risk of HIV infection (搜索) and adverse reproductive health outcomes, including infertility and preterm birth. Most infected persons (70%-85%) have minimal or no symptoms, and untreated infections can persist for months to years.
Regulatory Path Forward
Based on these Phase 3 results, Lupin plans to submit a supplemental New Drug Application (sNDA) to the FDA for Solosec for the treatment of trichomoniasis (搜索) later this year. Solosec is currently approved only for treating bacterial vaginosis (搜索) in adult women.
"Trichomoniasis (搜索) is the most common non-viral, STI that impacts an estimated 3-5 million people in the U.S.," said Gregory Kaufman, M.D., Senior Vice President, Global Clinical and Medical Affairs, Specialty at Lupin. "We look forward to working with the FDA as we file for this new indication."
Strategic Expansion of Women's Health Portfolio
The potential approval of Solosec for trichomoniasis (搜索) would further strengthen Lupin's position in women's health, building on the company's 2017 acquisition of Symbiomix Therapeutics (搜索) for $150 million. That acquisition brought Solosec into Lupin's portfolio as the first and only single-dose oral treatment approved for bacterial vaginosis (搜索).
Solosec received Qualified Infectious Disease Product (QIDP) designation from the FDA for bacterial vaginosis (搜索) treatment, making it eligible for at least 10 years of exclusivity in the United States. The single-dose formulation addresses compliance challenges, as current leading therapies for similar gynecologic infections have shown approximately 50% compliance rates.
The drug is administered as oral granules that should be sprinkled onto applesauce, yogurt, or pudding and consumed within 30 minutes without chewing or crunching the granules.